This event has passed.
Emerging Transporters and 2018 ITC White Paper on Drug Transporters
March 19, 2019 @ 8:00 am - 5:00 pm
8:00 – 8:50 am
Registration and Coffee
8:50 – 9:00 am
Welcome and Introduction
9:00 – 9:40 am
State of the Art in Clinical Transporter DDI Evaluation
Maciej J. Zamek-Gliszczynski, Ph.D. (Senior Fellow and Director, GlaxoSmithKline)
9:40 – 10:20 am
Updates on FDA’s DDI Guidance for Transporter-Mediated DDIs: Considerations and Perspectives
Xinning Yang, Ph.D. (FDA)
10:20 – 10:35 am
Coffee Break
10:35 – 11:15 am
Comprehensive PBPK Modeling of Rifampicin for Predicting Complex Drug-Drug Interactions Considering Various Enzyme Inductions and OATP Inhibition/Induction Effects
Yuichi Sugiyama, Ph.D. (RIKEN)
11:15 – 11:55 am
Changes in Expression and Activity of Transporters in Disease: Do They Impact Pharmacokinetics and Toxicity of Drugs?
Raymond Evers, Ph.D. (Director, Merck)
11:55 – 1:00 pm
Lunch
1:00 – 1:40 pm
Using DILIsym to Predict Hepatotoxicity Risk During Lead Optimization
Paul Michalski, Ph.D. (Fellow, GlaxoSmithKline)
1:40 – 2:20 pm
Prediction of DILI Risk: Beyond Mitochondrial Injury and BSEP Inhibition
Jack Uetrecht, M.D., Ph.D. (Professor of Pharmacy and Medicine, The University of Toronto)
2:20 – 2:40 pm
Coffee Break
2:40 – 3:20 pm
Factors Besides BSEP That Are Important for DILI: Nuclear Receptors, Enzymes and Other Transporters
Sandy Pang, Ph.D. (Professor of Pharmacy, The University of Toronto)
3:20 – 4:00 pm
Round Table Discussion
All Speakers